[go: up one dir, main page]

MX2017013777A - Metodo para el tratamiento de cancer. - Google Patents

Metodo para el tratamiento de cancer.

Info

Publication number
MX2017013777A
MX2017013777A MX2017013777A MX2017013777A MX2017013777A MX 2017013777 A MX2017013777 A MX 2017013777A MX 2017013777 A MX2017013777 A MX 2017013777A MX 2017013777 A MX2017013777 A MX 2017013777A MX 2017013777 A MX2017013777 A MX 2017013777A
Authority
MX
Mexico
Prior art keywords
trunk
mutation
antigen
present
cancer treatment
Prior art date
Application number
MX2017013777A
Other languages
English (en)
Other versions
MX381241B (es
Inventor
MCGRANAHAN Nicholas
Rosenthal Rachel
Swanton Charles
PEGGS Karl
Quezada Sergio
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507100.4A external-priority patent/GB201507100D0/en
Priority claimed from GBGB1603663.4A external-priority patent/GB201603663D0/en
Priority claimed from GBGB1603731.9A external-priority patent/GB201603731D0/en
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of MX2017013777A publication Critical patent/MX2017013777A/es
Publication of MX381241B publication Critical patent/MX381241B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)

Abstract

La presente invención se refiere a un método para identificar un neo-antígeno troncal en un tumor de un sujeto, que comprende los pasos de: i) determinar las mutaciones presentes en una muestra aislada del tumor; y ii) identificar una mutación troncal que es una mutación presente en esencialmente todas las células tumorales; y iii) identificar un neo-antígeno troncal, que es un antígeno codificado por una secuencia que comprende la mutación troncal.
MX2017013777A 2015-04-27 2016-04-27 Composición de células t para usarse en el tratamiento del cáncer. MX381241B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1507100.4A GB201507100D0 (en) 2015-04-27 2015-04-27 Method
GBGB1603663.4A GB201603663D0 (en) 2016-03-02 2016-03-02 Method
GBGB1603731.9A GB201603731D0 (en) 2016-03-03 2016-03-03 Method
PCT/EP2016/059401 WO2016174085A1 (en) 2015-04-27 2016-04-27 Method for treating cancer

Publications (2)

Publication Number Publication Date
MX2017013777A true MX2017013777A (es) 2018-03-27
MX381241B MX381241B (es) 2025-03-12

Family

ID=55809140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013777A MX381241B (es) 2015-04-27 2016-04-27 Composición de células t para usarse en el tratamiento del cáncer.

Country Status (22)

Country Link
US (3) US20180064793A1 (es)
EP (4) EP4137151A1 (es)
JP (4) JP6918703B2 (es)
KR (2) KR102629590B1 (es)
CN (2) CN117467603A (es)
AU (3) AU2016256220B2 (es)
BR (1) BR112017020893A2 (es)
CA (1) CA2982266A1 (es)
CL (2) CL2017002728A1 (es)
DK (1) DK3288581T3 (es)
ES (1) ES2836273T3 (es)
HU (1) HUE052106T2 (es)
IL (2) IL254760B2 (es)
MX (1) MX381241B (es)
MY (1) MY189338A (es)
NZ (1) NZ735882A (es)
PL (1) PL3288581T3 (es)
PT (1) PT3288581T (es)
RU (2) RU2770447C2 (es)
SG (2) SG10202007364RA (es)
WO (1) WO2016174085A1 (es)
ZA (1) ZA201706616B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
WO2018094167A1 (en) 2016-11-17 2018-05-24 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
CN110214275B (zh) * 2016-12-01 2022-12-06 南托米克斯有限责任公司 肿瘤抗原性加工和呈递
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US20200017586A1 (en) * 2017-02-07 2020-01-16 Memorial Sloan Kettering Cancer Center Use of immune checkpoint modulators in combination with antigen-specific t cells in adoptive immunotherapy
JP7155470B2 (ja) * 2017-03-31 2022-10-19 エーシーティー ジェノミックス （アイピー） カンパニー リミテッド 免疫原性がん特異的エピトープのためのランク付けシステム
WO2019012296A1 (en) 2017-07-14 2019-01-17 The Francis Crick Institute Limited ANALYSIS OF HLA ALLELS IN TUMORS AND USES THEREOF
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
EP3826669A2 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
EP3618071A1 (en) * 2018-08-28 2020-03-04 CeCaVa GmbH & Co. KG Methods for selecting tumor-specific neoantigens
WO2020043805A1 (en) * 2018-08-28 2020-03-05 CeCaVa GmbH & Co. KG Methods for ranking and/or selecting tumor-specific neoantigens
CN109294997B (zh) * 2018-09-30 2020-09-25 北京鼎成肽源生物技术有限公司 一种lrfft1细胞
CN109295097B (zh) * 2018-09-30 2020-09-25 北京鼎成肽源生物技术有限公司 一种mrfft2细胞
CN109337873A (zh) * 2018-09-30 2019-02-15 北京鼎成肽源生物技术有限公司 一种lrff细胞
CN109485721A (zh) * 2018-11-23 2019-03-19 杜学明 一种获得肿瘤特异性t细胞受体的方法
EP3906045A1 (en) * 2019-01-03 2021-11-10 Evaxion Biotech ApS Vaccines targeting neoepitopes
CN110534156B (zh) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 一种提取免疫治疗新抗原的方法及系统
CN110689930B (zh) * 2019-10-18 2021-07-30 北京橡鑫生物科技有限公司 检测tmb的方法及装置
WO2021087839A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤特异性多肽序列及其应用
WO2021116714A1 (en) * 2019-12-12 2021-06-17 Achilles Therapeutics Uk Limited Method for obtaining nucleic acid for sequencing
WO2021123832A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
US20230235008A1 (en) * 2020-02-14 2023-07-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Novel t cell receptors (tcrs) that react to neoantigens
CN111303268B (zh) * 2020-03-10 2021-08-27 江苏兰恩生物治疗技术研究院有限公司 子宫肌瘤新抗原、其应用和子宫肌瘤疫苗
CN115768879A (zh) 2020-04-28 2023-03-07 莱尔免疫制药公司 用于培养细胞的方法
AU2021264068A1 (en) * 2020-04-30 2022-12-08 The Translational Genomics Research Institute Neoantigen-informed tumor-infiltrating lymphocyte cancer immunotherapy
JP7537930B2 (ja) 2020-07-28 2024-08-21 株式会社ミツトヨ 形状測定方法
CA3188431A1 (en) 2020-08-07 2022-02-10 Carsten LINNEMANN Methods to enrich genetically engineered t cells
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202202880D0 (en) 2022-03-02 2022-04-13 Achilles Therapeutics Uk Ltd Methods for peptide synthesis
GB202205147D0 (en) 2022-04-07 2022-05-25 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202205135D0 (en) 2022-04-07 2022-05-25 Francis Crick Institute Ltd Analysis of HLA alleles transcriptional deregulation
WO2023194491A1 (en) 2022-04-07 2023-10-12 The Francis Crick Institute Limited Analysis of hla alleles transcriptional deregulation
GB202210006D0 (en) 2022-07-07 2022-08-24 Achilles Therapeutics Uk Ltd Analysis of T cell samples
JPWO2024034622A1 (es) * 2022-08-08 2024-02-15
GB202213928D0 (en) 2022-09-23 2022-11-09 Achilles Therapeutics Uk Ltd Allele specific expression
WO2024194208A1 (en) 2023-03-17 2024-09-26 Achilles Therapeutics Uk Limited Prediction of immunogenicity
WO2024256485A1 (en) 2023-06-15 2024-12-19 Achilles Therapeutics Uk Limited Identification of neoantigen peptides
CN117535352B (zh) * 2023-10-16 2024-07-26 同济大学 一种筛选具有pole抗原特异性t细胞的方法
GB202407727D0 (en) 2024-05-31 2024-07-17 Ucl Business Ltd Reporters constructs, systems and assays

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2209633C2 (ru) * 1997-09-19 2003-08-10 Юниверсити Оф Саузерн Калифорниа Т-клеточная вакцина для лечения рассеянного склероза
AU3483001A (en) * 2000-02-04 2001-08-14 Corixa Corp Compositions and methods for the therapy and diagnosis of ovarian cancer
KR102315754B1 (ko) 2010-05-14 2021-10-22 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
MX360823B (es) * 2011-05-24 2018-11-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacunas individualizadas para el cancer.
CN104662171B (zh) * 2012-07-12 2018-07-13 普瑟姆尼股份有限公司 个性化癌症疫苗和过继免疫细胞治疗
EP2882867A1 (en) * 2012-08-10 2015-06-17 The Broad Institute, Inc. Methods and apparatus for analyzing and quantifying dna alterations in cancer
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
CA2908434C (en) 2013-04-07 2021-12-28 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015014375A1 (en) * 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
EP3082853A2 (en) * 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
CR20210232A (es) * 2015-03-17 2022-06-24 Immatics Biotechnologies Gmbh NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method

Also Published As

Publication number Publication date
CL2020001730A1 (es) 2020-11-06
ES2836273T3 (es) 2021-06-24
PT3288581T (pt) 2020-12-04
JP2022008381A (ja) 2022-01-13
US20180064793A1 (en) 2018-03-08
CN117467603A (zh) 2024-01-30
JP2024001069A (ja) 2024-01-09
KR102629590B1 (ko) 2024-01-24
NZ735882A (en) 2022-07-29
RU2020123735A (ru) 2020-07-30
KR20230125090A (ko) 2023-08-28
IL298497B1 (en) 2025-12-01
BR112017020893A2 (pt) 2018-07-10
KR102884519B1 (ko) 2025-11-13
CN107750278B (zh) 2023-10-03
US20200000904A1 (en) 2020-01-02
CA2982266A1 (en) 2016-11-03
MY189338A (en) 2022-02-04
AU2021286241B2 (en) 2024-10-10
RU2017134504A (ru) 2019-04-04
SG10202007364RA (en) 2020-09-29
EP3603665A1 (en) 2020-02-05
IL254760B1 (en) 2023-01-01
DK3288581T3 (da) 2021-01-11
RU2017134504A3 (es) 2020-08-12
JP2018520637A (ja) 2018-08-02
AU2025200181A1 (en) 2025-01-30
JP6918703B2 (ja) 2021-08-11
PL3288581T3 (pl) 2021-05-31
IL254760B2 (en) 2023-05-01
CL2017002728A1 (es) 2018-06-22
AU2016256220B2 (en) 2021-10-21
EP3603666A1 (en) 2020-02-05
JP2020127404A (ja) 2020-08-27
IL254760A (en) 2017-12-31
AU2021286241A1 (en) 2022-01-06
HUE052106T2 (hu) 2021-04-28
EP3288581A1 (en) 2018-03-07
MX381241B (es) 2025-03-12
ZA201706616B (en) 2021-03-31
WO2016174085A1 (en) 2016-11-03
AU2016256220A1 (en) 2017-10-19
IL298497A (en) 2023-01-01
CN107750278A (zh) 2018-03-02
KR20170138560A (ko) 2017-12-15
RU2770447C2 (ru) 2022-04-18
EP3288581B1 (en) 2020-11-11
SG11201707920YA (en) 2017-11-29
US20200000903A1 (en) 2020-01-02
EP4137151A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
MX2017013777A (es) Metodo para el tratamiento de cancer.
CY1125267T1 (el) Antiσωmata eiδiκως σynδeonta pd-1 kai xphσeiς aytωn
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
CL2017002241A1 (es) Método de tratamiento de cáncer asociado con una mutación de ras
CY1123067T1 (el) Μεθοδοι αγωγης ασθενων καρκινων με αναστολεις τρανσφερασης φαρνεσυλιου
CL2019000061A1 (es) Anticuerpo para anti-claudin 18a2 y su utilización.
MX2019013117A (es) Moleculas de union al dominio de fibronectina de tipo iii del receptor del factor de crecimiento epidermico y del receptor del factor de crecimiento de hepatocitos (egfr y c-met).
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
ECSP17070399A (es) Anticuerpos contra icos
MX381724B (es) Cadenas ligeras comunes y metodos de uso.
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
CR20170297A (es) Método para la cuantificación absoluta de péptidos cancerosos restringidos a hla que son procesados de forma natural
MX394474B (es) Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo.
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
MX372723B (es) Métodos para marcar una molécula deuterada o no deuterada y formulaciones farmacéuticas para tratamiento.
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
MX2016008472A (es) Anticuero monoclonal neutralizador de anti-il-33-humana.
MX2017003387A (es) Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogenetica de cancer colorrectal metastasico.
PE20151893A1 (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
CL2016002419A1 (es) Métodos para determinar la probabilidad de padecer cáncer de próstata que comprende inmunoensayos de antígenos específicos de próstata
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки